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Background: Development of the hepatitis B virus (HBV) rtA181T/sW172* mutant could occur during prolonged
lamivudine (LAM) therapy, conferring cross resistance to adefovir. Recent studies demonstrated an increased
oncogenic potential of this mutant in NIH3T3 cells. In this study, we aimed to investigate the clinical significance of
this finding.
Methods: Serum samples from 123 LAM-resistant chronic hepatitis B patients were submitted for virological assays.
A highly sensitive amplification created restriction enzyme site (ACRES) method was devised to detect small
amounts of the rtA181T mutant in the serum. Virological factors including HBV-DNA level, genotype, precore
G1896A, BCP A1762T/G1764A, rtM204I/V, rtA181T and pre-S internal deletion mutations as well as clinical variables
including subsequent use of rescue drugs were submitted for outcome analysis.
Results: By use of the highly sensitive ACRES method, the rtA181T mutant was detectable in 10 of the 123 LAM-
resistant patients. During the mean follow-up period of 26.2 ± 16.4 months (range 2 to 108 months), 3 of the 10
(30.0%) rtA181T-positive patients and 2 of the 113 (1.8%) rtA181T-negative patients developed hepatocellular
carcinoma (HCC). Kaplan-Meier analysis indicated that the presence of rtA181T mutation (P < 0.001), age > 50 years
(P = 0.001), and liver cirrhosis (P < 0.001) were significantly associated with subsequent occurrence of HCC. All 5
HCC patients belonged to the older age and cirrhosis groups.
Conclusions: Emergence of the rtA181T/sW172* mutant in LAM-resistant patients increased the risk of HCC
development in the subsequent courses of antiviral therapy.
Background
In the past decade, much progress has been made in
antiviral therapy for chronic hepatitis B virus (HBV)
infection [1-3]. Several approved therapeutic agents are
now available, including regular or pegylated interferon
and nucleoside/nucleotide analogues (NA) such as lami-
vudine (LAM), adefovir dipivoxial (ADV), entecavir
(ETV), telbivudine and tenofovir [3-7]. Although NAs
are very effective in inhibiting HBV reverse
transcriptase, long-term usage of NAs is required to
reduce the risk of hepatitis relapses on drug withdrawal.
This strategy leads to development of drug resistance, a
major challenge for hepatologists. The risk of developing
LAM resistance is 14-32% in the first year and up to
70% by the fifth year [4]. The most frequently encoun-
tered LAM-resistant mutant is rtM204V/I, which pos-
sesses a mutation located at the catalytic YMDD motif
[8-11]. The rtL180M mutation usually occurs concur-
rently with the rtM204V mutation and serves as a com-
pensatory mutation [11]. The rtA181T mutation has
also been reported in a substantial proportion of LAM-
resistant patients, which has been shown to confer
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any medium, provided the original work is properly cited.LAM-resistance in cell-based assays [10]. Because of the
overlap between the S and polymerase genes, a great
proportion of patients carrying the rtA181T mutation
also possessed the sW172* nonsense mutation, resulting
in truncation of the pre-S/S reading frames [10].
The risk of developing ADV resistance was 2-3% and
28-29% by the second and fifth years of monotherapy in
treatment naïve patients respectively [12-14]. The risk
increased to 21% in LAM-resistant patients who were
switched to ADV monotherapy after 1.5 years of ADV
therapy [2,3]. The major ADV resistant mutants were
rtN236T and rtA181T/V [5]. Resistance to ETV is rare
for treatment naïve patients (1.5% by the fifth year) [2].
However, in the presence of rtM204I/V mutations, ETV
resistance can occur if the rtI169T, rtT184A/F/G/I/L/S,
rtS202G/I, or rtM250V mutation coexists [15,16]. The
risk of developing telbivudine resistance was 2-3% and
21% after 1 and 2 years of therapy in treatment-naïve
HBeAg-positive patients respectively. The major resis-
tant mutant was rtM204I [17]. Tenofovir has recently
been found to be effective in suppressing HBV replica-
tion with a low risk of drug resistance and several
reports have shown that this drug is effective against
various NA resistant or cross-resistant mutants [18,19].
It has been demonstrated that in patients with com-
pensated cirrhosis, LAM therapy significantly reduces
the risk of liver failure and hepatocellular carcinoma
(HCC) [20]. However, in patients who developed LAM
resistance, this beneficial effect was drastically compro-
mised. Several strategies of therapy have been examined
in LAM resistance patients, including withdrawal of
LAM therapy, switching to ADV monotherapy, ADV
add-on treatment, and switching to ETV monotherapy.
The latter two strategies are accepted in several thera-
peutic guidelines [21]. Despite various efforts to develop
effective rescue therapy for LAM-resistant patients,
severe consequences such as HCC and liver failure still
occur in a small number of patients [22-24].
Previous studies have indicated that several virological
factors including HBV-DNA level, HBV e antigen
(HBeAg) status, genotype, pre-S internal deletion
mutant and basal core promoter (BCP) A1762T/
G1764A mutation are closely associated with develop-
ment of HCC in treatment naïve, chronic hepatitis B
patients [25]. However, the associated virological factors
for severe disease outcomes in patients with LAM-resis-
tant chronic hepatitis B have not been clearly delineated.
A major reason these patients are started on long-term
LAM treatment early in the course of their disease is to
prevent the occurrence of HCC. The development of
LAM-resistance significantly compromises the effective-
ness of this strategy. It is imperative that the clinical
and virological factors associated with the development
of HCC in this group of patients be delineated. In this
study, we analyzed the clinical variables, virological
parameters, and use of rescue agents to identify factors
associated with severe disease outcomes.
Methods
Patients
This study was conducted under the approval of the
institutional review board of Chang Gung Medical Cen-
ter. The clinical records of 157 patients who received
LAM and developed drug resistance from January 2002
to December 2007 were reviewed. Of these patients, 123
were included because they had serum samples stored
in the Liver Research Center Serum Bank that could be
retrieved for virological analysis. All patients were posi-
tive for hepatitis B surface antigen (HBsAg) but negative
for antibody against hepatitis D virus or antibody against
hepatitis C virus. All patients were also tested negative
for human immunodeficiency virus infection. The fol-
lowing clinicopathological data were retrospectively
reviewed: gender, age, presence of liver cirrhosis, HBeAg
status, aspartate aminotransferase (AST), alanine amino-
transferase (ALT), alpha-fetoprotein (AFP), the duration
of LAM use before inclusion, subsequent use of ADV or
ETV, total duration of NA use, and development of
HCC or liver failure. None of the patients had detect-
able liver tumors (except hemangiomas) during the 3
years period prior to entry into this study. Monitoring
of HCC occurrence was performed by measurement of
AFP levels and ultrasonography every 3 months in cir-
rhotic patients and every 6 months in non-cirrhotic
patients. Diagnosis of HCC was made by either echo-
guided liver biopsy, fine needle aspiration cytology, high
AFP level (> 200 ng/mL) plus at least one dynamic ima-
ging study (dynamic computed tomography or magnetic
resonance imaging), or one dynamic imaging study plus
angiography (if alpha-fetoprotein < 200 ng/mL).
Serum hepatitis markers, including HBsAg, HBeAg,
and antibody to hepatitis D virus were assayed by com-
mercially available kits (Ausria-II and HBeAg-RIA,
Abbott Laboratories, North Chicago, IL; and anti-HD;
Formosa Biomedical Technology Corporation, Taiwan).
Serum antibody to hepatitis C virus was assayed using a
third-generation enzyme immunoassay kits (HCV EIA
III; Abbott Laboratories).
Virological assays
The HBV-DNA concentration was quantified by use of
Roche COBAS AmpliPrep/COBAS Taqman HBV Test
(Roche Diagnostics, Basel, Switzerland). The detection
limit of this test was 69 copies/mL. In this test, 5.82
copies/mL was equivalent to 1 IU/mL. HBV genotypes
were determined using the restriction fragment length
polymorphism method or phylogenetic sequence analy-
sis [26]. The methods to detect HBV basal core
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stop codon G1896A mutation, rtM204I mutation,
rtM204V mutation, rtL180M mutation were described
previously [10,26]. To identify pre-S internal deletion
mutations, the pre-S region flanked by P1, 5’-
GCGGGTCACCATATTCTTGGGAAC-3’ (nt. 2821 to
2844, sense) and P2, 5’-GAGCAGGGGTCCTAG-
GAATC-3’ (nt. 196 to 177, antisense) was amplified by
PCR. The expected size was 596 bp in length. These
PCR products were subjected to Southern blot analysis
to identify positively hybridized bands < 500 bp in
length. PCR products 500 to 596 bp in length were gel-
purified and subjected to direct sequencing to identify
pre-S deletion mutants with small deleted regions (<
100 bp in length). If a mixture of wild type and deletion
mutants was found by direct sequencing, the gel-
purified PCR product was cloned to pCR2.1-TOPO vec-
tor (Invitrogen, Carlsbad, CA) and 10-15 clones were
sequenced to identify the deletion mutants.
Previous studies indicated that the rtA181T mutant
usually coexisted with wild type or mutant type viruses
as a mixture [10,13]. As such, we developed an amplifi-
cation created restriction enzyme site (ACRES) method
to detect a small percentage of the rtA181T mutant. As
shown in Figure 1A and 1B, a partially mismatched pri-
mer was designed. A1, 5’-CTATGGGAGTGGGCCT-
CAGTCCCATTC-3’ (nt. 641-667, sense; mismatched
nucleotides underlined). This primer and A2, 5’-
GTTTAAATGTATACCCAGAGAC-3’ (nt. 840-819;
antisense) were used for PCR. Owing to the mismatched
nucleotides, a BST X1 site was created in the PCR pro-
duct (200 bp) if wild type sequence (but not mutant
Figure 1 Methods to detect rtA181T mutations and pre-S internal deletion mutations. (A) Rationale of the amplification created restriction
enzyme method to assist the detection of a small percentage of the rtA181T mutant. Partial amino acid sequences of the surface and polymerase
genes were shown. Arrow (left), a mismatched primer with two nucleotides (CA) mismatches; Arrow (right), a matched antisense primer. A BST XI
site was created if the amplicon was wild type. (B) Digestion of the PCR products with BST XI separated the wild type amplicon from the mixture.
The undigested (mutant) DNA was gel-purified and submitted for sequence verification. In a 10
5 copies of mixture, this method could detect 1/
1000 (10
2 copies) of mutant. (C) Detection of the pre-S internal deletion mutants. The PCR product was analyzed by Southern blot to detect large
deletion (b). The pre-S sequence with or without small deletions (a) was gel-purified and sent for sequence analysis.
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with BST X1. The wild type amplicon could be digested
to generate a band of 170 bp in length, leaving the
mutant amplicon undigested. The mutant amplicon was
then gel-purified and sent for direct sequencing for con-
firmation. In a PCR reaction, this method was capable
of detecting 100 copies of mutant when mixed with 10
3
to 10
7 copies of wild type HBV-DNA (≦ 1% of mutant
could be detected) and 10 copies of mutant when mixed
with 100 copies of wild type HBV-DNA (10% of mutant
can be detected under low copy numbers of HBV-
DNA).
Statistical analysis
Parametrical data were expressed in mean ± standard
deviation (SD) when assumed normal distribution but in
median (range) when they were not. Student-t test or
Mann-Whitney test was used when appropriate. Fisher’s
exact test was used for dichotomous data. Logistic
regression analysis was performed to evaluate the asso-
ciation of the clinical and virological variables with
occurrence of the rtA181T mutant. The Kaplan-Meier
method was used to estimate the accumulative incidence
of HCC and the log-rank test was used to compare
between groups. The Cox proportional hazard model
was used to identify independent clinical and virological
factors associated with HCC occurrence. Alpha error
was adjusted according to the method of Bonferroni
correction in multiple comparisons. Statistical analysis
was conducted by the use of SPSS (version 13.0).
Results
Genotypic characterization
Virological assays were performed for all 123 chronic
hepatitis B patients developing LAM-resistance. The dif-
ference in the prevalence of BCP A1762T/G1764A muta-
tion between genotype B and C HBV was statistically
significant (P < 0.001; Table 1). In this study, 3 patients
had small (< 100 bp) pre-S internal deletions, 27 had large
(> 100 bp) pre-S internal deletions, and 2 had both kinds
of pre-S deletions (Figure 1C). These 32 patients were
grouped for analysis. The rtA181T mutation was detected
in 10 patients. In these patients, the rtA181T mutation
was accompanied by the sW172* mutation in the S read-
ing frame. Additionally, small and large pre-S internal
deletions were observed in 1 and 5 patients, respectively.
No significant association was found between different
genotypes and other clinical and virological parameters.
Of the 123 LAM-resistant patients, 58 (47.2%) subse-
quently received ADV (switch or add-on) rescue therapy,
20 (16.3%) received ETV (switch) rescue therapy, and 24
(19.5%) received ETV and ADV therapy sequentially sec-
ondary to the emergence of additional drug resistant
mutants during their treatment courses. The remaining 21
(17.1%) patients continued to receive LAM monotherapy
either because they had only mild hepatitis activities or
because of barriers to access of rescue therapy.
Clinical and virological factors associated with HCC occurrence
Patients were followed for a mean period of 26.2 ± 16.4
months (range 2 to 108 months). During this period, 5
Table 1 Clinical and virological characteristics in LAM-resistant chronic hepatitis B patients
Characteristics Genotype B Genotype C P Value
a
Number of patients 84 39
Male (%) 69 (82.1%) 32 (82.1%) 0.999
Age (years) 46.0 ± 10.7 48.3 ± 10.2 0.276
rtM204V (%) 31 (36.9%) 13 (33.3%) 0.840
rtM204I (%) 40 (47.6%) 22 (56.4%) 0.439
rtM204V+rtM204I (%) 13 (15.5%) 4 (10.3%) 0.578
rtL180M (%) 22 (26.2%) 12 (30.8%) 0.666
rtA181T (%) 6 (7.1%) 4 (10.3%) 0.724
HBeAg (%) 40 (47.6%) 25 (64.1%) 0.120
AST (IU/L) 146.5 ± 211.8 140.3 ± 222.7 0.886
ALT (IU/L) 223.1 ± 341.3 181.1 ± 287.6 0.506
Alpha-fetoprotein (ng/dL) 4 (0-15) 3 (0-18) 0.987
HBV-DNA (10
6 copies/mL) 14.1 (0.001-16063) 10.0 (0.0015-1203) 0.493
BCP 1762/1764 mutations (%) 28 (33.3%) 31 (79.5%) < 0.001
Precore stop codon mutation (%) 45 (53.6%) 11 (28.2%) 0.0112
Pre-S internal deletions (%) 17 (20.2%) 15 (38.5%) 0.0461
Cirrhosis 26 (31.0%) 14 (35.9%) 0.680
Duration of LAM treatment before inclusion (months) 13 (6-55) 14 (6-48) 0.794
Values were given as either mean ± SD, median (range) or number (%).
aAccording to the method of Bonferroni correction for multiple comparisons, P < 0.0029 was considered statistically significant.
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formed to estimate the association between HCC occur-
rence and each of the clinical and virological variables
(Table 2). It was found that only age > 50 years (P =
0.001), the presence of rtA181T mutation (P < 0.001),
and liver cirrhosis (P < 0.001) were significantly asso-
ciated with occurrence of HCC (Figure 2). No statisti-
cally significant difference was found between those
with and without pre-S internal deletions. Multivariate
Cox proportional hazards regression analysis using the
forward stepwise model showed rtA181T to be the only
variable that remained in the equation as an indepen-
dent predictor (Hazard Ratio, 21.443; 95% CI, 3.556 to
129.302; P = 0.001).
Among the three signficicant factors, it was found that
all 5 HCC patients belonged to the older age (> 50 years
of age) and cirrhosis groups (Figure 2). In this study, 23
patients (18.7%) met both clinical criteria. In this subset
of patients, the cumulative incidence of HCC was 21.7%
in a mean follow-up period of 22.0 ± 13.0 months. Clin-
ical course of the 5 HCC patients were reviewed (Figure
3). It was discovered that rescue antiviral therapy was
successful in 3 of the 5 LAM-resistant patients (patient-
2, 3, and 5). In patient 1 and 4, rescue therapy was
delayed because of barriers to access. In patient 1, the
liver biochemistry data improved after initial hepatitis
exacerbation. Notably, in the three patients with
rtA181T mutants (patients-1 to 3), a relatively high level
of HBV-DNA (> 10
4 copies/mL) persisted for at least 10
months.
Clinical and virological factors associated with severe liver
consequences
Three patients developed acute liver failure during the
follow-up periods. Of these 3 patients, 2 had severe
hepatitis exacerbations at 2 and 2.5 months respectively
after detection of LAM-resistance. These two patients
died of hepatic decompensation. The third patient devel-
oped liver failure 3 months after detection of LAM-
resistance, but he underwent liver transplantation within
1 m. Taken together, 8 patients (5 with HCC and 3 who
progressed to liver failure) developed severe conse-
quences of liver diseases. Kaplan-Meier analysis was per-
formed to estimate the association between severe liver
consequences and each of the clinical and virological
variables (Table 2). It was found that age > 50 years (P
= 0.001), the presence of rtA181T mutation (P < 0.001),
BCP A1762T/G1764A mutations (P = 0.002) and liver
cirrhosis (P < 0.001) were significantly associated with
severe liver consequences. No statistically significant dif-
ference was found between those with and without pre-
S internal deletions. Notably, no association was found
between disease outcomes and HBV-DNA level or use
of rescue drugs (Table 2). Multivariate Cox proportional
hazards regression analysis using the forward stepwise
model showed rtA181T to be the only variable that
remained in the equation as an independent predictor
(Hazard Ratio, 13.091; 95% CI, 3.255 to 52.653; P <
0.001).
Factors associated with development of rtA181T mutant
Since rtA181T mutation was identified as an indepen-
dent predictor for severe consequences of liver disease
including HCC and liver failure, linear regression analy-
sis was performed to identify factors associated with
emergence of rtA181T mutation (Table 3). With Bonfer-
roni correction for multiple comparisons, P < 0.0029
was considered statistically significant. It was found that
only older age was significantly associated with develop-
ment of rtA181T mutant (OR, 1.144; 95%CI, 1.056-
1.240; P = 0.001).
Multiple linear regression analysis using the forward
stepwise method showed that age (OR, 1.126; 95% CI,
1.032 to 1.229; P = 0.008) and cirrhosis (OR, 5.671; 95%
CI, 1.063 to 30.248; P = 0.042) remained in the equation
as independent predictors.
Discussion
LAM is the first approved oral antiviral agent for the
treatment of chronic hepatitis B and has been therefore
widely used as the first line therapeutic agent in the past
decades. Despite the availability of other NAs carrying
lower risk of drug resistance (such as ADV and ETV),
LAM remains to be a popular anti-HBV agent in many
parts of the world because of its low cost, excellent
safety profile in long term use, and absence of onco-
genic potential in animal studies. However, because of
widespread use, an increasing number of LAM-resistant
patients have emerged.
Currently, the most widely accepted strategy for res-
cue therapy is ADV add-on treatment [21]. The de novo
development of the cross-resistant mutant, rtA181T,
was about 4% in a 4-year period of combination treat-
ment with LAM plus ADV [27]. Previous studies also
suggested effective viral suppression in LAM-resistant
patients by adopting ADV or ETV monotherapy. How-
ever, it was found that the risk of developing ADV or
ETV drug resistance was high with this strategy [21].
Recently, it was shown that tenofovir is superior to
ADV in treating LAM-resistant patients with a better
viral suppression and no detectable genotypic resistance
[18,19].
Despite the availability of rescue therapy, severe dis-
ease outcomes still occurred in a substantial percentage
of patients. Previous studies indicated that successful
viral suppression in ADV add-on therapy did not pre-
vent HCC occurrence in patients with liver cirrhosis
[22,24]. This study demonstrated that age > 50 years,
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Page 5 of 10Table 2 Kaplan-Meier analysis for the association between clinical features and occurrence of HCC or severe
consequences of liver diseases in LAM-resistant chronic hepatitis B patients
Clinical and virological factors No. of
patients
HCC Severe liver consequences
Cumulative
incidence
P (Log Rank test)
a Cumulative
incidence
P (Log Rank test)
a
Sex
Male 101 5 (5.0%) 0.339 7 (6.9%) 0.775
Female 22 0 (0%) 1 (4.5%)
Age (years)
≦ 50 81 0 (0%) 0.001
b 1 (1.2%) 0.001
b
> 50 42 5 (11.9%) 7 (16.7%)
rtM204V
Absence 62 2 (3.2%) 0.589 2 (3.2%) 0.131
Presence 61 3 (4.9%) 6 (9.8%)
rtM204I
Absence 44 2 (4.5%) 0.857 3 (6.8%) 0.917
Presence 79 3 (3.8%) 5 (6.3%)
rtM204V+I
Absence 106 4(3.8%) 0.568 5 (4.7%) 0.033
Presence 17 1 (5.9%) 3 (17.6%)
rtL180M
Absence 89 3 (3.4%) 0.591 6 (6.7%) 0.830
Presence 34 2 (5.9%) 2 (5.9%)
rtA181T
Absence 113 2 (1.8%) < 0.001
b 4 (3.5%) < 0.001
b
Presence 10 3 (30.0%) 4 (40.0%)
HBeAg
Absence 58 5 (8.6%) 0.012 7 (12.1%) 0.016
Presence 65 0 (0%) 1 (1.5%)
HBV-DNA (×10
6 copies/mL)
≦ 15 69 2 (2.9%) 0.325 4 (5.8%) 0.570
> 15 54 3 (5.6%) 4 (7.4%)
AST
≦ 2 ×UNL 67 2 (3.0%) 0.337 2 (3.0%) 0.050
> 2 ×UNL 56 3 (5.4%) 6 (10.7%)
ALT
≦ 2 ×UNL 59 2 (3.4%) 0.722 3 (5.1%) 0.450
> 2 ×UNL 64 3 (4.7%) 5 (7.8%)
BCP mutation
Absence 64 0 (0%) 0.012 0 (0%) 0.002
b
Presence 59 5 (8.5%) 7 (11.9%)
Precore stop codon mutation
Absence 67 1 (1.5%) 0.094 3 (4.5%) 0.285
Presence 56 4 (7.1%) 5 (8.9%)
Genotype C
Absence 84 3 (3.6%) 0.631 4 (4.8%) 0.234
Presence 39 2 (5.1%) 4 (10.3%)
Pre-S internal deletions
Absence 91 4 (4.4%) 0.749 6 (6.6%) 0.941
Presence 32 1 (3.1%) 2 (6.3%)
Duration of LAM treatment on entry
(months)
≦ 12 80 2 (2.5%) 0.798 4 (5.0%) 0.361
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rtA181T mutation, prior to initiation of rescue therapy
were significantly associated with severe liver conse-
quences. Interestingly, neither the choice of rescue
drugs nor the duration of antiviral drug use seemed to
affect the clinical outcomes of these patients. In fact of
the 21 patients receiving LAM monotherapy, only 1
developed HCC. It is possible that rescue therapy was
not initiated in these patients because they had mild
hepatitis despite development of drug resistance.
Table 2 Kaplan-Meier analysis for the association between clinical features and occurrence of HCC or severe conse-
quences of liver diseases in LAM-resistant chronic hepatitis B patients (Continued)
> 12 43 3 (7.0%) 4 (9.3%)
Subsequent ADV treatment
No 41 1 (2.4%) 0.688 2 (4.9%) 0.774
Yes 82 4 (4.9%) 6 (7.3%)
Subsequent ETV treatment
No 79 4 (5.1%) 0.422 0 (0%) 0.153
Yes 44 1 (2.3%) 8 (18.2%)
Subsequent ETV and/or ADV treatment
No 21 1 (4.8%) 0.284 1 (4.8%) 0.181
Yes 102 4 (3.9%) 7 (6.9%)
Total duration of antiviral therapy (months)
≦ 40 73 1 (1.4%) 0.157 3 (4.1%) 0.343
> 40 50 4 (8.0%) 5 (10%)
Cirrhosis
No 83 0 (0%) < 0.001
b 0 (0%) < 0.001
b
Yes 40 5 (12.5%) 8 (20.0%)
aKaplan-Meier analysis;
bAccording to the method of Bonferroni correction for multiple comparisons, P < 0.0024 was considered statistically significant.
Figure 2 Factors associated with occurrence of HCC. The cumulative incidence of HCC was depicted according to the presence of the
rtA181T mutation (A), use of rescue therapy (B), the presence of liver cirrhosis (C), and age > 50 years (D).
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pre-S internal deletion mutants, which were frequently
identified as prognostic indicators in treatment-naïve
patients were not found to be associated with clinical
outcomes in LAM-resistant patients. It is likely that dur-
ing rescue therapy in these patients, HBV replication
was suppressed to a low level, resulting in reduction in
the development of the pre-S internal deletion muta-
tions. In this view, the pre-S internal deletion mutants
are unlikely to play an important role in hepatocarcino-
genesis in this subset of patients.
The most striking finding in this study was that pre-
existing rtA181T mutant in LAM-resistant patients was
independently associated with severe liver consequences,
especially occurrence of HCC. The rtA181T mutant has
been shown to confer ADV-resistant [28-30]. In ADV
add-on studies, it was found that rtA181T mutants
could be either pre-existing in LAM-resistant patients
or de novo-developed after ADV add-on therapy [27].
Furthermore, because the reading frame of HBV
polymerase overlaps with that of the S gene, some resis-
tant mutations (such as rtA181T) in the polymerase
gene coexist with S gene mutations, including stop
codon mutations [31]. In some patients with rtA181T
mutants, a concomitant sW172* mutation was observed
in the overlapping S reading frame, resulting in trunca-
tion of the pre-S/S proteins [32]. Several previous stu-
dies have reported the transactivation activities of a
truncated pre-S2 mutant isolated from the chromosomal
integrated HBV genome of hepatoma cells. Such
mutants were capable of transactivating several promo-
ters including those of oncogenic proteins [33]. Transac-
tivation activity occurred only when the premature stop
codons are located within a region of the S gene, named
“transactivity-on-region” [34]. The premature stop
codon of the S gene in the rtA181T/sW172* mutant
was located near the border of the transactivity-on-
region and its transactivating activity was recently con-
firmed [35,36]. Additionally, owing to secretory defect
and a dominant negative effect on wild-type HBV virion
Figure 3 Clinical courses of 5 HCC patients from entry to the study to development of HCC. The changes of ALT level (gray lines) and
HBV-DNA level (black line) were depicted. Arrow, time-point of HCC diagnosis; Solid bar, duration of LAM used; Shaded bar, duration of ETV
used; Empty bar, duration of ADV used.
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reduced the typical extent of virological breakthrough in
serum, resulting in difficulty to recognize drug resis-
tance [32]. In this study, a hypersensitive ACRES
method was used to detect small percentages of the
rtA181T mutants. Of the 10 rtA181T-positive patients,
the mutants constituted < 5%, 10-30% and > 90% of the
viral population in 6, 2, and 2 patients, respectively. We
speculated that despite a small percentage of the
mutants was detected in the serum, a larger percentage
could exist in the liver, owing to the secretory defect of
the sW172* mutant. Presumably, intrahepatic accumula-
tion of this mutant partially contributed to its oncogenic
effect.
Finally, in our study, 23 patients had two unfavorable
conditions: liver cirrhosis and older than 50 years of
age. During the follow-ups, 5 of the 23 patients (21.7%)
developed HCC and 7 of the 23 (30.4%) patients devel-
oped severe liver consequences. The present data indi-
cated that in this special subgroup of patients, careful
selection of antiviral agent and closely monitoring for
viral mutants (including BCP and rtA181T mutations)
are mandatory.
Conclusion
By analyzing the clinical variables, virological para-
meters, and clinical use of rescue agents in LAM-resis-
tant mutants, we found older age, cirrhosis, and
rtA181T mutation are significantly associated with
occurrence of HCC in the subsequent courses of anti-
viral therapy.
Acknowledgements
We are indebted to numerous members of the Liver Research Unit of Chang
Gung Memorial Hospital for their help and encouragement. This study is
supported by grants from Chang Gung Medical Research Council (CMRPG
380332), National Science Council, Taiwan (99-3112-B-182-009), and
Department of Health, Taiwan (PMRPG390071).
Author details
1Liver Research Center, Department of Hepato-Gastroenterology, Chang
Gung Memorial Hospital, Taipei, Taiwan.
2Molecular Medicine Research
Center, Chang Gung University, Taoyuan, Taiwan.
3School of Medicine, New
York University, New York, USA.
4Department of Pediatric Gastroenterology,
Chang Gung Children Hospital, Taoyuan, Taiwan.
5Department of Pathology,
Chang Gung Memorial Hospital, Taipei, Taiwan.
Authors’ contributions
CTY designed the study and analyzed the clinical data. CTY and TC involved
in drafting the manuscript and revising it critically for important intellectual
content. CWH, YCC, KHL, and MWL interpreted and analyzed the clinical and
laboratory data. TCC interpreted and analyzed the pathological data. All
authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 19 July 2011 Accepted: 21 September 2011
Published: 21 September 2011
References
1. Wright TL: Introduction to chronic hepatitis B infection. Am J
Gastroenterol 2006, 101(Suppl 1):S1-6.
2. Zoulim F: Antiviral therapy of chronic hepatitis B. Antiviral Res 2006,
71:206-15.
Table 3 Univariate logistic regression analysis for the association between clinical features and emergence of rtA181T
mutation in LAM-resistant patients
Clinical factors rtA181T OR (95%CI) P Value
Yes (n = 10) No (n = 113)
Sex (male) 10 (100%) 91 (80.5%) > 10
6 (0-> 10
6) 0.998
Age (years) 58.5 ± 8.3 45.7 ± 10.1 1.144 (1.056-1.240) 0.001
a
rtM204V 2 (20.0%) 42 (37.2%) 1.582 (0.423-5.909) 0.495
rtM204I 4 (40.0%) 58 (51.3%) 2.366 (0.480-11.670) 0.290
rtM204V+I 4 (40.0%) 13 (11.5%) 5.128 (1.276-20.607) 0.021
rtL180M 3 (30.0%) 31 (27.4%) 1.134 (0.276-4.663) 0.862
HBeAg 2 (20.0%) 63 (55.8%) 0.198 (0.040-0.976) 0.047
HBV-DNA (10
6 copies/mL) 15 (0.0015-16063) 2.08 (0.001-4640) 1.000 (0.999-1.001) 0.688
AST (IU/L) 147.0 ± 220.2 114.1 ± 122.1 0.999 (0.996-1.003) 0.693
ALT (IU/L) 217.3 ± 335.9 124.7 ± 124.7 0.999 (0.995-1.002) 0.408
Alpha-fetoprotein (ng/dL) 3 (0-18) 4 (0-17) 0.998 (0.997-1.001) 0.876
BCP mutation 7 (70.0%) 52 (46.0%) 2.737 (0.674-11.124) 0.159
Precore stop codon mutation 4 (40.0%) 52 (46.0%) 0.782 (0.209-2.922) 0.715
Genotype C 4 (40.0%) 35 (31.0%) 1.486 (0.394-5.598) 0.559
Pre-S internal deletions 3 (30.0%) 29 (25.7%) 2.024 (0.532-7.693) 0.301
Cirrhosis 8 (80.0%) 32 (28.3%) 10.125 (2.039-50.281) 0.005
Duration of LAM treatment (months) 13 (6-55) 13.5 (6-48) 1.043 (0.990-1.099) 0.117
Values were given as either mean ± SD, median (range) or number (%).
aAccording to the method of Bonferroni correction for multiple comparisons, P < 0.0029 was considered statistically significant.
Yeh et al. BMC Cancer 2011, 11:398
http://www.biomedcentral.com/1471-2407/11/398
Page 9 of 103. Keeffe EB, Marcellin P: New and Emerging Treatment of Chronic Hepatitis
B. Clin Gastroenterol Hepatol 2007, 5:285-94.
4. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, Dienstag JL,
Heathcote EJ, Little NR, Griffiths DA, Gardner SD, Castiglia M: Long-term
safety of lamivudine treatment in patients with chronic hepatitis B.
Gastroenterol 2003, 125:1714-22.
5. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L,
Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL, Adefovir Dipivoxil
437 Study Group: Adefovir dipivoxil for the treatment of hepatitis B e
antigen-positive chronic hepatitis B. N Engl J Med 2003, 348:808-16.
6. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS,
Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R,
Apelian D, BEHoLD AI463022 Study Group: A comparison of entecavir and
lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006,
354:1001-10.
7. Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL,
Jacobson JM, Johnson VA, Pollard RB, Rooney JF, Sherman KE, Swindells S,
Polsky B, ACTG Protocol A5127 Team: Randomized controlled study of
tenofovir and adefovir in chronic hepatitis B virus and HIV infection:
ACTG A5127. Hepatol 2006, 44:1110-6.
8. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM: Acute exacerbation and
hepatitis B virus clearance after emergence of YMDD motif mutation
during lamivudine therapy. Hepatol 1999, 30:567-72.
9. Lai CL, Dienstag J, Schiff E, Leung NWY, Atkins M, Hunt C, Brown N,
Woessner M, Boehme R, Condreay L: Prevalence and clinical correlates of
YMDD variants during lamivudine therapy for patients with chronic
hepatitis B. Clin Infect Dis 2003, 36:687-96.
10. Yeh CT, Chien RN, Chu CM, Liaw YF: Clearance of the original hepatitis B
virus YMDD-motif mutants with emergence of distinct lamivudine-
resistant mutants during prolonged lamivudine therapy. Hepatol 2000,
31:1318-26.
11. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ,
Omata M: The polymerase L528M mutation cooperates with nucleotide
binding-site mutations, increasing hepatitis B virus replication and drug
resistance. J Clin Invest 2001, 107:449-455.
12. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C,
Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S: Resistance
to adefovir dipivoxil therapy associated with the selection of a novel
mutation in the HBV polymerase. Gastroenterology 2003, 125:292-297.
13. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M,
Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K,
Arterburn S, Chuck SL, Adefovir Dipivoxil 438 Study Group: Long-term
therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B
for up to 5 years. Gastroenterology 2006, 131:1743-51.
14. Delaney WE: Progress in the treatment of chronic hepatitis B: long-term
experience with adefovir dipivoxil. J Antimicrob Chemotherapy 2007,
59:827-32.
15. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A,
Fang J, Hsu M, Mazzucco C, Eggers B, Zhang S, Plym M, Klesczewski K,
Tenney DJ: Entecavir resistance is rare in nucleoside naive patients with
hepatitis B. Hepatology 2006, 44:1656-65.
16. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-
Kaczmarska A, Martin P, Goodman Z, Colonno R, Cross A, Denisky G,
Kreter B, Hindes R, AI463026 BEHoLD Study Group: Entecavir for treatment
of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
Gastroenterology 2006, 130:2039-49.
17. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y,
Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM,
Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA, Globe
Study Group: Telbivudine versus lamivudine in patients with chronic
hepatitis B. N Engl J Med 2007, 357:2576-88.
18. Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F,
Hoffmann C, Rockstroh J, Stoehr A, Wolf E, Soriano V, Berger F, Berg T,
Carlebach A, Schwarze-Zander C, Schürmann D, Jaeger H, Mauss S:
Combination of tenofovir and lamivudine versus tenofovir after
lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS
2006, 20:1951-4.
19. Lacombe K, Ollivet A, Gozlan J, Durantel S, Tran N, Girard PM, Zoulim F: A
novel hepatitis B virus mutation with resistance to adefovir but not to
tenofovir in an HIV-hepatitis B virus-co-infected patient. AIDS 2006,
20:2229-31.
20. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T,
Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J, Cirrhosis Asian
Lamivudine Multicentre Study Group: Lamivudine for patients with
chronic hepatitis B and advanced liver disease. N Engl J Med 2004,
351:1521-31.
21. Choi MS, Yoo BC: Management of chronic hepatitis B with nucleoside or
nucleotide analogues: a review of current guidelines. Gut Liver 2010,
4:15-24.
22. Elefsiniotis I, Buti M, Jardi R, Vezali E, Esteban R: Clinical outcome of
lamivudine-resistant chronic hepatitis B patients with compensated
cirrhosis under adefovir salvage treatment. Importance of HCC
surveillance. Eur J Intern Med 2009, 20:478-81.
23. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T,
Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H: Virological
response and hepatocarcinogenesis in lamivudine-resistant hepatitis B
virus genotype C patients treated with lamivudine plus adefovir
dipivoxil. Intervirology 2008, 51:385-93.
24. Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yastuji H,
Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y,
Kumada H: Development of HCC in patients receiving adefovir dipivoxil
for lamivudine-resistant hepatitis B virus mutants. Hepatol Res 2010,
40:145-52.
25. Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G: Associations between
hepatitis B virus mutations and the risk of hepatocellular carcinoma: a
meta-analysis. J Natl Cancer Inst 2009, 101:1066-82.
26. Hsu CW, Yeh CT, Chang ML, Liaw YF: Identification of a hepatitis B virus S
gene mutant in lamivudine-treated patients experiencing HBsAg
seroclearance. Gastroenterology 2007, 132:543-50.
27. Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M: Low
resistance to adefovir combined with lamivudine: a 3-year study of 145
lamivudine-resistant hepatitis B patients. Gastroenterology 2007,
133:1445-51.
28. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trépo C, Zoulim F:
Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment
failure. J Hepatol 2008, 48:747-55.
29. Karatayli E, Karayalçin S, Karaaslan H, Kayhan H, Türkyilmaz AR, Sahin F,
Yurdaydin C, Bozdayi AM: A novel mutation pattern emerging during
lamivudine treatment shows cross-resistance to adefovir dipivoxil
treatment. Antivir Ther 2007, 12:761-8.
30. Gerolami R, Bourliere M, Colson P, Halfon P, Borentain P, Henry M, Botta D,
Thibault V, Khiri H, Tamalet C: Unusual selection of rtA181V HBV mutants
cross-resistant to adefovir following prolonged lamivudine
monotherapy: report of two cases. Antivir Ther 2006, 11:1103-6.
31. Yeh CT: Development of HBV S gene mutants in chronic hepatitis B
patients receiving nucleotide/nucleoside analogue therapy. Antivir Ther
2010, 15(3 PtB):471-5.
32. Warner N, Locarnini S: The antiviral drug selected hepatitis B virus
rtA181T/sW172* mutant has a dominant negative secretion defect and
alters the typical profile of viral rebound. Hepatology 2008, 48:88-98.
33. Kekule AS, Lauer U, Meyer M, Caselmann WH, Hofschneider PH, Koshy R:
The preS2/S region of integrated hepatitis B virus DNA encodes a
transcriptional transactivator. Nature 1990, 343:457-61.
34. Lauer U, Weiss L, Hofschneider PH, Kekule AS: The hepatitis B virus pre-S/S
(t) transactivator is generated by 3’ truncations within a defined region
of the S gene. J Virol 1992, 66:5284-9.
35. Lai MW, Huang SF, Hsu CW, Chang MH, Liaw YF, Yeh CT: Identification of
nonsense mutations in hepatitis B virus S gene in patients with
hepatocellular carcinoma developed after lamivudine therapy. Antivir
Ther 2009, 14:249-61.
36. Lai MW, Yeh CT: The oncogenic potential of hepatitis B virus rtA181T/
surface truncation mutant. Antivir Ther 2008, 13:875-9.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/11/398/prepub
doi:10.1186/1471-2407-11-398
Cite this article as: Yeh et al.: Emergence of the rtA181T/sW172*
mutant increased the risk of hepatoma occurrence in patients with
lamivudine-resistant chronic hepatitis B. BMC Cancer 2011 11:398.
Yeh et al. BMC Cancer 2011, 11:398
http://www.biomedcentral.com/1471-2407/11/398
Page 10 of 10